NCCN Guidelines® Insights - Melanoma, Version 3.2016
The NCCN Guidelines for Melanoma have been significantly revised over the past few years in response to emerging data on a number of novel agents and treatment regimens. These NCCN Guidelines Insights summarize the data and rationale supporting extensive changes to the recommendations for systemic therapy in patients with metastatic or unresectable melanoma.
This activity has been designed to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for Melanoma
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Melanoma
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.
Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.
INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
Daniel G. Coit, MD, Panel Chair, has disclosed that has disclosed that he has no relevant financial relationships.
John A. Thompson, MD, Panel Vice Chair, has disclosed that he is a scientific advisor for Celldex Therapeutics; and receives consulting fees/honoraria from Eisai Inc., Genentech, Inc., and Seattle Genetics.
Alain Algazi, MD, Panel Member, has disclosed that he receives grant/research support from Acerta; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Corvus; GlaxoSmithKline; MedImmune Inc.; Merck & Co, Inc.; and Novartis Pharmaceuticals Corporation. He is also a consultant for Taylor Blessey LLC.
Douglas Johnson, MD, Panel Member, has disclosed that he is on the advisory board for Bristol-Myers Squibb Company and Genoptix.
Richard W. Joseph, MD, Panel Member, has disclosed that he receives grant/research support from Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Roche Laboratories, Inc., and X4 Pharmaceuticals; he also serves as a scientific advisor for Bristol-Myers Squibb Company, Castle Biosciences, Inc., Eisai Inc., and Nektar Therapeutics.
Patrick Ott, MD, PhD, Panel Member, has disclosed that he receives grant/research support from AstraZeneca Pharmaceuticals/MedImmune, Celldex Therapeutics, Merck & Co., Inc., and Bristol-Myers Squibb Company; and that he is on the advisory board for Alexion Pharmaceuticals, Genentech, Inc., and Celldex Therapeutics.
Susan M. Swetter, MD, Panel Member, has disclosed that has disclosed that she has no relevant financial relationships.
Nicole R. McMillian, MS, Guidelines Coordinator, NCCN, has disclosed that she has no relevant financial relationships.
Anita M. Engh, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians.
NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center`s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour. Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers. This is a knowledge-based activity. UAN: 0836-0000-16-008-H01-P
All clinicians completing this activity will be issued a certificate of participation.
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation